This study was not able to show benefits in terms of mortality or bleeding when using radial vs. femoral approach in patients undergoing ST elevation myocardial Infarction. This small trial does not change things for “radialists” way past their learning curve who already feel confident with this technique. For them, there is no way back.<a href="https://solaci.org/en/2019/03/20/acc-2019-safari-unexpectedly-radial-approach-offers-no-benefits-in-stemi/" title="Read more" >...</a>
This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>
Both studies followed beyond 5 years patients with severe aortic stenosis who had undergone transcatheter aortic valve replacement (TAVR). Findings included low rates of significant valve degeneration and failure, in both cases. While data on the long-term degeneration of transcatheter-implanted valves are scarce, follow-up from the NOTION trial of low-risk patients and from the UK TAVI<a href="https://solaci.org/en/2019/02/12/notion-and-uk-tavi-report-good-long-term-outcomes/" title="Read more" >...</a>
Despite our high hopes for new-generation drug-eluting stents (DES), patients with diabetes still have a different prognosis, both clinical and angiographic, compared with non-diabetic patients. Authors sought to investigate the impact of diabetes on patients who underwent drug-eluting stent implantation in the BIONICS (BioNIR Ridaforolimus Eluting Coronary Stent System in Coronary Stenosis) trial. This<a href="https://solaci.org/en/2019/01/28/outcomes-of-contemporary-des-in-patients-with-diabetes-do-they-render-freedom-obsolete/" title="Read more" >...</a>
Fragmented sleep and lower sleeping time have a higher risk of subclinical atherosclerosis in multiple territories. These results highlight the importance of good sleeping habits for good health and against cardiovascular disease. This comes out when binge watching online series on TV or any mobile device has become the norm. Online “streaming” is silently stressing<a href="https://solaci.org/en/2019/01/25/the-price-of-binge-watching-subclinical-atherosclerosis-and-sleep-quality/" title="Read more" >...</a>
The new European guidelines on myocardial revascularization were developed by a joint effort of the European Society of Cardiology (ESC) and the European Association of Cardiovascular Surgery (EACTS). These guidelines are intended to support clinical practice with pragmatic recommendations based on currently available evidence and on personal experience, whenever evidence is missing. Both coronary angioplasty<a href="https://solaci.org/en/2019/01/24/the-ten-commandments-of-myocardial-revascularization-according-to-europe/" title="Read more" >...</a>
Troponin elevation is a common finding in acute patients admitted by an emergency service, even in the absence of an acute coronary event. There are patients in whom we simply cannot identify the origin of such troponin elevation. Initially, we relied on this marker as an exclusive marker of acute coronary syndrome. In consequence, many<a href="https://solaci.org/en/2019/01/21/troponinitis-or-troponinemia-terms-that-trivialize-troponin-elevation-without-a-specified-diagnosis/" title="Read more" >...</a>
1- ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function. Read more 2- TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation The prognosis of patients with<a href="https://solaci.org/en/2019/01/18/the-most-important-articles-of-2018-in-structural-heart-diseases/" title="Read more" >...</a>
This work showed that percutaneous septal ablation in patients with symptomatic hypertrophic cardiomyopathy is safe (and improves patient symptoms) and results in excellent long-term survival. Alcohol-induced infarction for treatment of symptomatic hypertrophic obstructive cardiomyopathy is controversial because, while it may relieve acute symptoms, it might also increase long-term mortality. This study sought to report<a href="https://solaci.org/en/2019/01/11/contemporary-results-for-septal-embolization-in-hypertrophic-cardiomyopathy/" title="Read more" >...</a>
1- Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction, which persisted through a 2-year follow-up and favored treatment with an ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (Orsiro) compared with the gold standard, a durable-polymer everolimus-eluting stent<a href="https://solaci.org/en/2019/01/04/los-10-articulos-mas-leidos-de-diciembre-2/" title="Read more" >...</a>